BBC Features LongeVC's Partner Insilico Medicine in Major Investigation on AI Drug Discovery
BBC just ran a feature on how AI is unlocking treatments for diseases that have stumped medicine for decades — antibiotics against drug-resistant superbugs, new candidates for Parkinson's, repurposed drugs for rare diseases. Our partner company, Insilico Medicine, was among the innovative companies recognized in the piece, highlighted for its drug candidate Rentosertib, which has shown promise against Idiopathic Pulmonary Fibrosis in phase two clinical trials. Insilico used AI to both identify a potential weakness in the disease and design a drug to target it.
We invested in Insilico early, and this is exactly what we hoped to see: AI drug discovery moving from a headline into a clinical pipeline, into actual data, into a potential therapy for patients who currently have very limited options.